Summary of the ESC/EAS Guidelines 2025 Focused Update on Dyslipidemia Management

The documents present the 2025 targeted update of the ESC/EAS guidelines for the treatment of dyslipidemia, which complements the previous 2019 version. The main changes include the adoption of the SCORE2 and SCORE2-OP algorithms for a more accurate cardiovascular risk assessment up to age 89 and the inclusion of new drugs such as bempedoic acid. The recommendation to measure lipoprotein(a) at least once in a lifetime and to initiate immediate intensive lipid-lowering therapies in patients with acute coronary syndromes has been introduced. The documents also examine strategies for specific populations, such as those living with HIV or cancer patients exposed to chemotherapy toxicity. Finally, experts in the field reflect on the practical challenges of clinical implementation of these guidelines and the future prospects for preventive medicine. Source: François Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Free.European Heart Journal, Volume 46, Issue 42, 7 November 2025, Pages 4359–4378. Review: Daniela Tirotta FADOI - Scientific Society of Internal Medicine Update and Training Channel www.fadoi.org